Advertisement

Topics

Esperion Therapeutics Inc. Company Profile

06:07 EST 15th December 2018 | BioPortfolio

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with the currently available LDL-cholesterol lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon a successful and comprehensive Phase 1 and Phase 2 program. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.


News Articles [740 Associated News Articles listed on BioPortfolio]

Marketplace Roundup: Biotech Organogenesis To Go Public Again; Eyes On Esperion Cholesterol Trial

Health care companies Organogenesis, Esperion Therapeutics, Blue Cross and Blue Shield of Minnesota, and AbbVie make headlines today.

Pawar Law Group: Esperion Therapeutics, Inc. Reminder: Pawar Law Reminds of Important July 6, 2018 Lead Plaintiff Deadline in Class Action- ESPR

NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Pawar Law Group reminds shareholders who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) from February 22, 2017 through May 1, 2018, both d...

Esperion says combo therapy lowers cholesterol level by 35 percent

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study.

Esperion Eyes Early 2019 to File NDA for Cholesterol-Lowering Therapy

Shares of Ann Arbor, Mich.-based Esperion Therapeutics are up more than 7 percent in premarket trading after the company announced on Sunday that planned to seek regulatory approval for its cholestero...

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 - ESPR

NEW YORK, NY / ACCESSWIRE / June 4, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Esperion T...

Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies

Ann Arbor, Mich.-based Esperion Therapeutics is starting off the week with several positives. The company first reported final results from a long-term safety study of bempedoic acid 180 mg versus pla...

The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of July 6, 2018 (ESPR)

NEW YORK, NY / ACCESSWIRE / June 5, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Esperion Therapeutics, Inc. (NASDAQ: ESPR) who purc...

Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's ...

PubMed Articles [460 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1286 Associated Companies listed on BioPortfolio]

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., located in Plymouth, Michigan, discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company is funded by top tier venture...

Esperion Therapeutics Inc.

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Esperion Therapeutics Inc." on BioPortfolio

We have published hundreds of Esperion Therapeutics Inc. news stories on BioPortfolio along with dozens of Esperion Therapeutics Inc. Clinical Trials and PubMed Articles about Esperion Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Esperion Therapeutics Inc. Companies in our database. You can also find out about relevant Esperion Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record